How Worried Should Investors Be About Mereo Biopharma Group Plc ADR (MREO)

Mereo Biopharma Group Plc ADR (NASDAQ:MREO) does about 1.09M shares in volume on a normal day but saw 996924 shares change hands in the recent trading day. The company now has a market cap of 540.04M USD. Its current market price is $3.85, marking an increase of 4.90% compared to the previous close of $3.67. The 52 week high reached by this stock is $4.50 whilst the lowest price level in 52 weeks is $1.07. The script in recent trading has seen the stock touch a high of $8 and a low of $4.

Mereo Biopharma Group Plc ADR (MREO) has a 20-day trading average at $3.74 and the current price is -14.44% off the 52-week high compared with 259.81% distance from its 52-week low. The 50-day simple moving average of the closing price is $3.40 and its 200-day simple moving average is $2.81. If we look at the stock’s price movements over the week, volatility stands at 6.58%, which increases to 7.62% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 58.42 to suggest the stock is neutral.

The consensus objective for the share price is $7.20, suggesting that the stock has a potential upside of 46.53% over the period. The median price target is 48.67% away from the current levels at $7.5.

2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 13, 2024 when Robert W. Baird initiated the stock to “Outperform” and issued a price target of $8. Cantor Fitzgerald initiated its price target at $4.

Mereo Biopharma Group Plc ADR (MREO) stock is up 6.06% over the week and 11.92% over the past month. Its price is 66.67% year-to-date and 191.67% over the past year.

The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year.

Its 12-month price target is $7.5. To reach the target analysts have set, the stock logically needs to grow 46.53 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $4, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $8.

The company has a return on investment of -71.76% and return on equity of -39.59%. The beta has a value of 0.89. Price to book ratio is 12.61 and price to sales ratio is 61.44.